Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Sanofi Stories

2013-06-22 12:21:35

- EDITION I demonstrated similar blood sugar control with fewer night-time low blood sugar events compared to Lantus® - PARIS, June 22, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the first Phase 3 study results (EDITION I) for its investigational new insulin U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus(® )(insulin glargine [rDNA origin] injection). The company also announced topline...

2013-06-22 12:21:20

-- Lixisenatide decreased HbA1c by reducing PPG when added to basal insulin with or without oral anti-diabetic agents -- BRIDGEWATER, N.J., June 22, 2013 /PRNewswire/ -- Sanofi US (EURONEXT: SAN and NYSE: SNY) announced today data that showed lixisenatide, an investigational once-daily prandial glucagon-like peptide 1 (GLP-1) receptor agonist, decreased HbA1c by reducing PPG (postprandial glucose) daytime exposure when added to standard of care which includes basal insulin with or...

2013-06-21 12:49:39

One of the largest clinical trials done in infants with congenital (present at birth) heart diseases, published in the New England Journal of Medicine, shows that the increasingly common practice of using the drug clopidogrel (Plavix®) to reduce shunt-related blood flow issues is not effective in the dose studied. “Once again, pediatric-specific research shows that newborns and infants are not little adults," said David Wessel, MD, Chief Medical Officer, Children's National Medical...

2013-06-12 16:26:54

Sanofi's SHERPA service recognized for improving collaboration with external partners in life sciences Research and Development PARIS and SAN DIEGO, June 12, 2013 /PRNewswire/ -- Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, today announced that it has honored Sanofi-Aventis Recherche & Developpement (hereinafter "Sanofi") with the first Accelrys Scientific Innovation Lifecycle Leaders Award. The award, in the Life...

2013-06-11 12:29:53

European Pharmaceutical Review Webinar Examines How Life Sciences Companies Transform Paper-Based Trial Master Files with Electronic Document Management Systems CONSHOHOCKEN, Pa., June 11, 2013 /PRNewswire/ -- NextDocs announced today that it will be co-presenting with Sanofi, the global and diversified pharmaceutical company, in a webinar examining how life sciences companies can streamline paper-based Trial Master File (TMF) processes using electronic TMF (eTMF) systems and...

2013-06-11 08:33:35

DUBLIN, June 11, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/hrlbkd/top_five_global) has announced the addition of the "Top Five Global Pharmaceutical Companies: Performance, Strategies and Competitive Analysis" [http://www.researchandmarkets.com/research/hrlbkd/top_five_global ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The fragmented market has observed some changes in the...

2013-06-10 08:29:25

New Fluzone® Quadrivalent (Influenza Virus Vaccine): LYON, France, June 10, 2013 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that the U.S. Food and Drug Administration has approved the supplemental biologics license application (sBLA) for licensure of its four-strain influenza vaccine, Fluzone Quadrivalent vaccine. Fluzone Quadrivalent vaccine is the newest addition to the Fluzone family of influenza...

2013-06-06 23:43:04

Pharmica Consulting, the industry leader in life sciences processes and technology, is pleased to announce that Kamran Ansari from Sanofi will be speaking at Pharmica´s CRO Management Conference on September 19, 2013 in Princeton, NJ. Princeton, NJ (PRWEB) June 05, 2013 In 2013 the pharmaceutical industry will continue the downsizing of drug development operations, placing an ever greater reliance on strategic CRO alliances and collaborative technologies. As sponsors increase their...

2013-06-04 12:27:32

- Connect & Coach(TM) Awarded $100,000 to Further Develop its Novel Solution to Help Improve Health Outcomes for People Living with Diabetes - BRIDGEWATER, N.J., June 4, 2013 /PRNewswire/ -- Sanofi US announced today that Connect & Coach(TM) has been selected as the winning solution of the 2013 Data Design Diabetes (DDD) Innovation Challenge - Prove It! at Health Datapalooza IV in Washington, DC. Sanofi US will award Connect & Coach(TM) $100,000 to further develop its...

FDA Review Staff Look Into Efficacy Of High Dose Sleep Drug
2013-05-21 09:09:30

Lawrence LeBlond for redOrbit.com - Your Universe Online An experimental insomnia drug from Merck & Co has been shown to be effective, but reviewers with the US Food and Drug Administration (FDA) are questioning the drug´s dosage levels. The comments, posted on the agency´s website Monday, come ahead of a meeting of external medical experts which will advise on whether the drug, called suvorexant, should be approved or not. The FDA review staff found limited association of...